All Stories

  1. Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

    Article • Leukemia & Lymphoma, February 2019, Taylor & Francis

    Mr Mads E Bjørn

  2. Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase

    Article • Journal of Enzyme Inhibition and Medicinal Chemistry, January 2017, Taylor & Francis

    Mr Mads E Bjørn

  3. Ruxolitinib and autoimmune diseases

    Article • Clinical Case Reports, May 2015, Wiley

    Mr Mads E Bjørn